Welcome to our dedicated page for Voyager Therapeutics SEC filings (Ticker: VYGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Voyager Therapeutics, Inc. (Nasdaq: VYGR) SEC filings page on Stock Titan brings together the company’s public regulatory disclosures, including current reports on Form 8-K that furnish financial results, corporate updates, and investor presentations. As a Delaware-incorporated public company with common stock listed on the Nasdaq Global Select Market, Voyager files with the U.S. Securities and Exchange Commission to report material information related to its biotechnology business focused on neurological diseases.
Through these filings, readers can access details on Voyager’s collaboration revenue, research and development and general and administrative expenses, net loss, and cash, cash equivalents, and marketable securities. The company’s 8-K filings often attach press releases that describe quarterly financial and operating results, cash runway expectations, and progress across its pipeline, including Alzheimer’s disease programs such as the anti-tau antibody VY7523 and tau silencing gene therapy VY1706, as well as partnered gene therapy programs with Neurocrine Biosciences and collaborations with Novartis and other partners.
Voyager’s filings also reference its TRACER™ AAV capsid discovery platform, next-generation capsids designed for blood-brain barrier penetration, and collaborations such as the small molecule discovery and license option agreement with Transition Bio targeting TDP-43 in ALS and frontotemporal dementia. Forward-looking statements and risk disclosures in these documents outline uncertainties related to regulatory decisions, clinical development, collaboration milestones, intellectual property, and the company’s ability to fund operations.
On Stock Titan, SEC documents are paired with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify major financial metrics, pipeline updates, and collaboration terms. Users can follow new 8-Ks and other SEC reports in real time, review historical filings for context on Voyager’s evolution, and connect these disclosures to the company’s news flow and stock performance.
Voyager Therapeutics, Inc. executive Robin Swartz, the company’s COO & CBO, reported an open-market sale of 3,882 shares of common stock at a weighted average price of
Voyager Therapeutics, Inc. Chief Scientific Officer Carter Todd Alfred reported an automatic open-market sale of 3,301 shares of common stock at a weighted average price of $3.44 per share. The shares were sold under a pre-established durable automatic sale instruction adopted on May 12, 2025 to cover tax withholding obligations arising from the vesting of restricted stock units on February 17, 2026, and are described as not being a discretionary trade. Following this transaction, Alfred directly holds 149,892 shares of Voyager Therapeutics common stock.
Voyager Therapeutics, Inc. President and CEO Alfred Sandrock reported an open-market sale of 11,732 shares of common stock of Voyager Therapeutics at a weighted average price of $3.41 per share. According to the disclosure, this transaction was executed under a durable automatic sale instruction adopted on May 12, 2025.
The shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units on February 17, 2026, and the filing states that the sale did not represent a discretionary trade by the reporting person. After this tax-related sale, Sandrock directly holds 498,257 shares of Voyager Therapeutics common stock.
Voyager Digital affiliate reported transactions of Common stock in a Form 144 notice. The filing shows a sale of 12,192 shares on
Voyager Therapeutics submitted a Form 144 notice disclosing a proposed sale of 3,301 common shares. The filing identifies the shares as Restricted Stock Vesting tied to compensation with a vesting date of 02/17/2026. The filing also records a prior sale by Todd Carter of 3,525 common shares on 02/10/2026. The Form lists 02/18/2026 and notes the securities trade on NASDAQ.
VYGR submitted a Rule 144 notice for the sale of 3,882 shares of its common stock tied to restricted stock vesting on 02/17/2026. The filing also lists a prior sale of 4,569 common shares on 02/10/2026 reported by Robin E. Swartz.
Voyager Therapeutics ownership disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 4,000,000 common shares, representing 7.19% of the class as of 12/31/2025. The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder, and that Armistice exercises voting and investment power over the Master Fund's holdings. The Master Fund disclaims beneficial ownership by reason of its inability to vote or dispose of the shares under its Investment Management Agreement with Armistice Capital.
EcoR1 Capital and affiliates reported a sizable ownership position in Voyager Therapeutics, Inc. common stock. EcoR1 Capital, LLC and its control person Oleg Nodelman each beneficially own 4,002,847 shares, representing 6.8% of Voyager’s common stock. EcoR1 Capital Fund Qualified, L.P. directly holds 3,756,988 shares, or 6.4% of the class.
The filing shows no sole voting or dispositive power; all authority is shared among the reporting persons. They state the shares were acquired and are held in the ordinary course of business and not for the purpose, or with the effect, of changing or influencing control of Voyager Therapeutics.
Voyager Therapeutics, Inc. announced that Chief Medical Officer Toby Ferguson, M.D., Ph.D. has decided to resign from his role and all other positions with the company and its subsidiaries, effective February 20, 2026, to pursue a new opportunity.
The company states that Dr. Ferguson’s resignation is not due to any disagreement with Voyager. President and Chief Executive Officer Alfred W. Sandrock, Jr., M.D., Ph.D. has agreed to assume key responsibilities, including strategic guidance for clinical development programs, on an interim basis after the resignation becomes effective.
Swartz Robin reported open-market sale transactions in a Form 4 filing for VYGR. The filing lists transactions totaling 4,569 shares at a weighted average price of $3.85 per share. Following the reported transactions, holdings were 210,078 shares.